DBV Technologies S.A. (NASDAQ:DBVT - Get Free Report)'s stock price crossed below its fifty day moving average during trading on Monday. The stock has a fifty day moving average of $10.78 and traded as low as $10.19. DBV Technologies shares last traded at $10.27, with a volume of 142,685 shares traded.
Wall Street Analyst Weigh In
DBVT has been the topic of several research reports. Citigroup reaffirmed a "market outperform" rating on shares of DBV Technologies in a report on Thursday, October 29th. Citizens Jmp dropped their price target on DBV Technologies from $55.00 to $47.00 and set a "market outperform" rating for the company in a research note on Thursday, October 29th. Weiss Ratings restated a "sell (e+)" rating on shares of DBV Technologies in a report on Thursday, October 15th. Cantor Fitzgerald restated an "overweight" rating on shares of DBV Technologies in a report on Thursday, September 10th. Finally, HC Wainwright reaffirmed a "buy" rating on shares of DBV Technologies in a research note on Friday, October 30th. Five analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $45.25.
Get Our Latest Research Report on DBV Technologies
DBV Technologies Stock Down 6.8%
The firm has a 50 day moving average of $10.78 and a 200-day moving average of $16.33. The company has a market cap of $645.78 million, a P/E ratio of -3.41 and a beta of -0.84.
DBV Technologies (NASDAQ:DBVT - Get Free Report) last announced its earnings results on Wednesday, October 28th. The company reported ($0.70) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.29) by ($0.41). The company had revenue of $1.60 million for the quarter, compared to the consensus estimate of $0.56 million. DBV Technologies had a negative net margin of 5,392.17% and a negative return on equity of 120.95%. On average, research analysts predict that DBV Technologies S.A. will post -2.22 EPS for the current fiscal year.
Institutional Trading of DBV Technologies
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Royal Bank of Canada lifted its holdings in DBV Technologies by 167.1% during the first quarter. Royal Bank of Canada now owns 4,680 shares of the company's stock valued at $98,000 after purchasing an additional 2,928 shares in the last quarter. Vontobel Holding Ltd. acquired a new position in shares of DBV Technologies during the 3rd quarter worth about $144,000. China Universal Asset Management Co. Ltd. lifted its stake in DBV Technologies by 170.0% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 21,600 shares of the company's stock valued at $249,000 after buying an additional 13,600 shares in the last quarter. Cetera Investment Advisers lifted its stake in DBV Technologies by 93.4% in the 1st quarter. Cetera Investment Advisers now owns 25,358 shares of the company's stock valued at $530,000 after buying an additional 12,243 shares in the last quarter. Finally, Great Point Partners LLC boosted its holdings in DBV Technologies by 59.3% in the 3rd quarter. Great Point Partners LLC now owns 250,000 shares of the company's stock worth $2,940,000 after buying an additional 93,094 shares during the last quarter. Institutional investors and hedge funds own 71.74% of the company's stock.
DBV Technologies Company Profile
(
Get Free Report)
DBV Technologies is a clinical-stage biopharmaceutical company focused on developing treatments for food allergies and other immune-mediated conditions. Founded in France, the company's research centers on epicutaneous immunotherapy, an approach that delivers small amounts of an allergen through the skin using a patch. Its lead investigational program is Viaskin Peanut, a patch-based treatment being developed for peanut allergy. DBV has also conducted research into treatments for other conditions, including milk allergy and eosinophilic esophagitis.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider DBV Technologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and DBV Technologies wasn't on the list.
While DBV Technologies currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.